KBC Group NV trimmed its position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 37.1% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 2,282,519 shares of the biopharmaceutical company's stock after selling 1,344,697 shares during the period. Gilead Sciences comprises 0.6% of KBC Group NV's investment portfolio, making the stock its 26th biggest position. KBC Group NV owned approximately 0.18% of Gilead Sciences worth $191,366,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in GILD. CarsonAllaria Wealth Management Ltd. lifted its holdings in Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 238 shares during the period. nVerses Capital LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter worth about $25,000. Valued Wealth Advisors LLC increased its holdings in Gilead Sciences by 101.9% during the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 161 shares during the last quarter. Cedar Wealth Management LLC raised its position in Gilead Sciences by 51.6% in the second quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 160 shares during the period. Finally, Strategic Investment Solutions Inc. IL purchased a new position in Gilead Sciences in the second quarter valued at about $33,000. Hedge funds and other institutional investors own 83.67% of the company's stock.
Gilead Sciences Price Performance
Shares of NASDAQ GILD traded down $0.24 during midday trading on Thursday, hitting $92.39. 3,733,690 shares of the company's stock were exchanged, compared to its average volume of 7,062,525. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 1.18. The business's fifty day moving average price is $86.22 and its two-hundred day moving average price is $75.69. The company has a market cap of $115.02 billion, a price-to-earnings ratio of 1,029.22, a PEG ratio of 2.91 and a beta of 0.17. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $98.90.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Gilead Sciences's revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the business posted $2.29 earnings per share. As a group, research analysts forecast that Gilead Sciences, Inc. will post 4.39 EPS for the current fiscal year.
Gilead Sciences Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.33%. Gilead Sciences's payout ratio is 3,422.22%.
Insiders Place Their Bets
In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of the stock in a transaction that occurred on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,947 shares of company stock valued at $4,968,674 over the last 90 days. Insiders own 0.16% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms recently commented on GILD. Sanford C. Bernstein began coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They issued an "outperform" rating and a $105.00 price target on the stock. BMO Capital Markets boosted their target price on Gilead Sciences from $94.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, November 7th. Royal Bank of Canada lifted their price objective on Gilead Sciences from $75.00 to $81.00 and gave the stock a "sector perform" rating in a report on Thursday, November 7th. Robert W. Baird upped their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a "neutral" rating in a report on Thursday, November 7th. Finally, Maxim Group downgraded shares of Gilead Sciences from a "buy" rating to a "hold" rating in a research note on Friday, November 8th. Eleven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $93.10.
Get Our Latest Research Report on GILD
Gilead Sciences Company Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
